Comparative efficacy of topical tetraVisc versus lidocaine gel in cataract surgery

<p<Abstract</p< <p<Background</p< <p<To compare the clinical efficacy of lidocaine 2% with tetracaine 0.5% for cataract surgery.</p< <p<Methods</p< <p<In a randomized, multi-surgeon, controlled clinical trial,122 consecutive cataract cases eligib...
Ausführliche Beschreibung

<p<Abstract</p< <p<Background</p< <p<To compare the clinical efficacy of lidocaine 2% with tetracaine 0.5% for cataract surgery.</p< <p<Methods</p< <p<In a randomized, multi-surgeon, controlled clinical trial,122 consecutive cataract cases eligible for topical anesthesia, were randomly assigned to receive lidocaine 2% gel (1 ml) or tetracaine solution 0.5% (TetraVisc, 0.5 ml) before clear corneal phacoemulsification. Main outcome measure was visual analog scale (0 to 10), which was used to measure intra-operative pain. Secondary outcome measures included patients' discomfort due to tissue manipulation and surgeon graded patients' cooperation. Duration of surgery and intra-operative complications were also recorded.</p< <p<Results</p< <p<The mean age in TetraVisc (TV) group was 70.4 years and in the lidocaine gel group (LG) it was 70.6 years (p = 0.89). Patient reported mean intra-operative pain scores by visual analog scale were 0.70 ± 0.31 in TV group and 1.8 ± 0.4 in LG group (<it<P </it<< 0.001). Mean patient cooperation was also marginally better in the TV group (8.3 ± 0.3) compared to LG group (8.4 ± 0.6) (P = 0.25). 96% of patients in TV group showed intra-operative corneal clarity compared to 91% in LG group. TV group had less (1 out of 61 patients, 1.6%) intra-operative complications than LG group (3 out of 61 patients, 4.8%). No anesthesia related complications were noted in either group</p< <p<Conclusion</p< <p<Topical TetraVisc solution was superior to lidocaine 2% gel for pain control in patients undergoing clear corneal phacoemulsification. Lidocaine 2% gel is similar to TetraVisc in patient comfort and surgeon satisfaction.</p< <p<Trial Registration</p< <p<<b<Clinical trials number</b<: ISRCTN78374774</p< Ausführliche Beschreibung